WO1995000154B1 - Antidepressant agents with a rapid onset of action - Google Patents
Antidepressant agents with a rapid onset of actionInfo
- Publication number
- WO1995000154B1 WO1995000154B1 PCT/IE1994/000033 IE9400033W WO9500154B1 WO 1995000154 B1 WO1995000154 B1 WO 1995000154B1 IE 9400033 W IE9400033 W IE 9400033W WO 9500154 B1 WO9500154 B1 WO 9500154B1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- serotonin reuptake
- reuptake inhibitor
- selective serotonin
- use according
- lithium
- Prior art date
Links
- 239000000935 antidepressant agent Substances 0.000 title claims abstract 5
- 239000003772 serotonin uptake inhibitor Substances 0.000 claims abstract 8
- WHXSMMKQMYFTQS-UHFFFAOYSA-N lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 claims abstract 6
- 229910052744 lithium Inorganic materials 0.000 claims abstract 6
- 229960002073 Sertraline Drugs 0.000 claims abstract 4
- VGKDLMBJGBXTGI-SJCJKPOMSA-N Sertraline Chemical compound C1([C@@H]2CC[C@@H](C3=CC=CC=C32)NC)=CC=C(Cl)C(Cl)=C1 VGKDLMBJGBXTGI-SJCJKPOMSA-N 0.000 claims abstract 4
- 230000001430 anti-depressive Effects 0.000 claims abstract 4
- 238000002360 preparation method Methods 0.000 claims abstract 2
- 239000003814 drug Substances 0.000 claims 3
- 230000035639 Blood Levels Effects 0.000 claims 1
- AHOUBRCZNHFOSL-YOEHRIQHSA-N Casbol Chemical compound C1=CC(F)=CC=C1[C@H]1[C@H](COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-YOEHRIQHSA-N 0.000 claims 1
- WSEQXVZVJXJVFP-UHFFFAOYSA-N Citalopram Chemical compound O1CC2=CC(C#N)=CC=C2C1(CCCN(C)C)C1=CC=C(F)C=C1 WSEQXVZVJXJVFP-UHFFFAOYSA-N 0.000 claims 1
- 206010012378 Depression Diseases 0.000 claims 1
- 229960002464 Fluoxetine Drugs 0.000 claims 1
- 229960004038 Fluvoxamine Drugs 0.000 claims 1
- RTHCYVBBDHJXIQ-UHFFFAOYSA-N N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine Chemical compound C=1C=CC=CC=1C(CCNC)OC1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-UHFFFAOYSA-N 0.000 claims 1
- 229960001653 citalopram Drugs 0.000 claims 1
- 239000002552 dosage form Substances 0.000 claims 1
- CJOFXWAVKWHTFT-XSFVSMFZSA-N fluvoxamine Chemical compound COCCCC\C(=N/OCCN)C1=CC=C(C(F)(F)F)C=C1 CJOFXWAVKWHTFT-XSFVSMFZSA-N 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 229960002296 paroxetine Drugs 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 239000011780 sodium chloride Substances 0.000 claims 1
- 230000000994 depressed Effects 0.000 abstract 1
Abstract
A selective serotonin reuptake inhibitor such as sertraline is used in combination with lithium for simultaneous or separate, including concurrent, administration in a method of achieving rapid onset of antidepressant action in a patient. Onset of antidepressant action is observed with such preparations approximately one week earlier than that achievable through the administration of the selective serotonin reuptake inhibitor alone. Such rapid onset of action is extremely significant in the case of patients who are severely depressed.
Claims
1. Use of a selective serotonin reuptake inhibitor and lithium in the manufacture of a medicament for use in the treatment of depression, wherein the medicament is administered at the commencement of treatment to bring about a rapid onset of antidepressant action.
2. Use according to Claim 1, wherein the medicament is in the form of a product containing the selective serotonin reuptake inhibitor and the lithium as a combined preparation for simultaneous or separate use.
3. Use according to Claim 2, wherein the product is effective to achieve onset of antidepressant action approximately one week earlier than that achievable through use of the selective serotonin reuptake inhibitor alone.
4. Use according to Claim 2 or 3, wherein the selective serotonin reuptake inhibitor is selected from sertraline, fluoxetine, fluvoxamine, paroxetine and citalopram.
5. Use according to Claim 4, wherein the selective serotonin reuptake inhibitor is sertraline.
6. Use according to any one of Claims 2-5, wherein the selective serotonin reuptake inhibitor and the lithium are combined in a single unit dosage form.
7. Use according to Claim 6, wherein the Hthium is used in an amount effective to achieve blood levels of lithium of the order of 0.2 mmol/1 (0.2 mEq/1) or greater.
8. Use according to any one of Claims 5-7, wherein the product contains 25 mg of sertraline and 400 mg of lithium in the form of a pharmaceutically acceptable salt thereof.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU70088/94A AU7008894A (en) | 1993-06-28 | 1994-06-27 | Antidepressant agents with a rapid onset of action |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IE930485 | 1993-06-28 | ||
| IE930485A IE930485A1 (en) | 1993-06-28 | 1993-06-28 | Antidepressant agents with a rapid onset of action |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| WO1995000154A1 WO1995000154A1 (en) | 1995-01-05 |
| WO1995000154B1 true WO1995000154B1 (en) | 1995-02-09 |
Family
ID=11040000
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/IE1994/000033 WO1995000154A1 (en) | 1993-06-28 | 1994-06-27 | Antidepressant agents with a rapid onset of action |
Country Status (3)
| Country | Link |
|---|---|
| AU (1) | AU7008894A (en) |
| IE (1) | IE930485A1 (en) |
| WO (1) | WO1995000154A1 (en) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR9810403A (en) | 1997-07-01 | 2000-08-29 | Pfizer | Sertraline salts and sustained release dosage forms of sertraline |
| WO2004010932A2 (en) | 2002-07-30 | 2004-02-05 | Peter Migaly | Combination therapy for depression, prevention of suicide, and varous medical and psychiatric conditions |
| AR042806A1 (en) | 2002-12-27 | 2005-07-06 | Otsuka Pharma Co Ltd | COMBINATION OF CARBOSTIRILE DERIVATIVES AND INHIBITORS OF SEROTONINE REABSORTION FOR THE TREATMENT OF ANIMO DISORDERS |
| DK1575590T3 (en) | 2002-12-27 | 2008-02-11 | Otsuka Pharma Co Ltd | Carbostyril derivatives and serotonin reuptake inhibitors to treat mood disorders |
| WO2005102366A2 (en) * | 2004-04-19 | 2005-11-03 | Philip Maxwell Satow | Lithium combinations, and uses related thereto |
| EP1758600A4 (en) * | 2004-06-04 | 2008-03-05 | Mood Man Sciences Llc | Methods and compositions for treating mood disorder |
-
1993
- 1993-06-28 IE IE930485A patent/IE930485A1/en not_active IP Right Cessation
-
1994
- 1994-06-27 WO PCT/IE1994/000033 patent/WO1995000154A1/en active Application Filing
- 1994-06-27 AU AU70088/94A patent/AU7008894A/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR100481254B1 (en) | Pharmaceutical composition comprising mirtazapine and one or more selective serotonin reuptake inhibitors | |
| EP0397831B1 (en) | Treatment of obesity | |
| US4590213A (en) | Anti-anxiety method | |
| CA2375908A1 (en) | Highly selective norepinephrine reuptake inhibitors and methods of using the same | |
| CA2302700A1 (en) | New use for budesonide and formoterol | |
| KR20060109493A (en) | Combination drug therapy to treat obesity | |
| HU219332B (en) | Synergetic medicaments containing trans-(+)-2-[(dimethylamino)-methyl]-1-(3-methoxiphenyl)-cyclohexanol and acetaminophen | |
| BR9506847A (en) | Compound pharmaceutical composition use of a compound process for the treatment of pain | |
| JP2002524415A5 (en) | ||
| RU97119427A (en) | COMBINATION OF 5-NT ACCELERATION INHIBITOR WITH THE 5-NTIA SELECTIVE ANTAGONIST | |
| US4438138A (en) | Reduction of cholesterol with meta-chloro α-t-butylaminopropiophenone | |
| JP2004537500A5 (en) | ||
| RU95101385A (en) | Products containing g-csf and tnf-binding protein | |
| JP2003504332A5 (en) | ||
| MY124465A (en) | Reduction of infarct volume using citicoline | |
| JP2002523437A5 (en) | ||
| WO1995000154B1 (en) | Antidepressant agents with a rapid onset of action | |
| IL43820A (en) | Pharmaceutical compositions for treatment of spastically disabled human beings containing bronchodilating sympathomimetic amines | |
| CA2450915A1 (en) | Use of levosimendan and beta-adrenergic receptor antagonist for the treatment of heart failure | |
| NZ236055A (en) | Use of pyrimidine-substituted piperazine derivative in the treatment of depression | |
| KR900007434A (en) | Therapeutics with cystatin as active ingredients | |
| KR970005283A (en) | Use of sertraline to treat patients after myocardial infarction | |
| IE930485A1 (en) | Antidepressant agents with a rapid onset of action | |
| WO1995009625A1 (en) | Use of amiodarone for the treatment of heart failure | |
| JPH0393719A (en) | Therapeutic medicine for drug dependence disease composed of cellutrarin |